Roche Is Joining The Obesity Party But Questions Remain
Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competitors. Roche's emerging cardiometabolic pipeline could become one of the fastest growing segments in the next 10+ years.
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
Roche says weight loss drug shows promising results in early trial
The weekly injection helped patients with obesity lose 18.8% of their weight relative to those who received a placebo, after 24 weeks in the phase one trial.
Roche ramps up obesity-drug competition with early-stage trial results
The race to develop powerful new weight-loss drugs grew even more heated on Thursday as Roche Holding AG released early-stage trial results for an experimental obesity treatment.
